Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy – Authors' reply
- Resource Type
- Correspondence
- Source
- In
The Lancet Oncology June 2022 23(6):e246-e246 - Subject
Analysis and Interpretation Correspondence - Language
- ISSN
- 1470-2045